KALA
KALA BIO, Inc.·Healthcare
0.20
10.929%(+0.02)
Market ClosedLast Updated: — ET
52W L: $0.1552W H: $20.60
KALA NEWS
defenseworld.net
5d ago
KALA BIO (NASDAQ:KALA) vs. Celularity (NASDAQ:CELU) Financial Survey
Celularity (NASDAQ: CELU - Get Free Report) and KALA BIO (NASDAQ: KALA - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability. Valuation and Earnings This table compares Celularity and
globenewswire.com
Apr 1
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities
Engagement will assess KALA's clinical assets, development options, and AI-enabled analytical opportunities, including the MSC Secretome platform Engagement will assess KALA's clinical assets, development options, and AI-enabled analytical opportunities, including the MSC Secretome platform
globenewswire.com
Mar 30
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live
Next-Generation Agentic AI Platform Achieves Live Enterprise Deployment, Delivering Secure, Scalable, Autonomous Research Solutions to Global Biotechnology and Pharmaceutical Organizations Next-Generation Agentic AI Platform Achieves Live Enterprise Deployment, Delivering Secure, Scalable, Autonomous Research Solutions to Global Biotechnology and Pharmaceutical Organizations
benzinga.com
Mar 30
EXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform Launch
The company confirmed that BIRA is now live in client-controlled environments, marking its entry into revenue-generating AI infrastructure.
defenseworld.net
Mar 27
KALA BIO, Inc. (NASDAQ:KALA) Receives Consensus Rating of “Hold” from Analysts
KALA BIO, Inc. (NASDAQ: KALA - Get Free Report) has been given a consensus recommendation of "Hold" by the six brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company.
globenewswire.com
Mar 18
Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate
AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry TORONTO and ARLINGTON, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light” or the “Company”) and Kala Bio, Inc. (NASDAQ: KALA) (“Kala Bio”) today announced that Red Light has engaged Kala Bio's with its Researgency.ai agentic artificial intelligence platform under world wide license from Younet to support the clinical development strategy for PEX010, the patented botanical psilocybin drug candidate originated by Filament Health Corp. (“Filament”).
